Unichem Laboratories rose 3.24% to Rs 172.05 at 11:57 IST on BSE after the company said it has received the consideration amount of Rs 160.50 crore of the sale proceeds from the sale of its Indore SEZ Plant.
The announcement was made during trading hours today, 25 October 2013.
Meanwhile, the S&P BSE Sensex was down 16.27 points or 0.08% at 20,709.16.
On BSE, 36,000 shares were traded in the counter as against average daily volume of 28,061 shares in the past one quarter.
The stock hit a high of Rs 175 and a low of Rs 170.05 so far during the day. The stock had hit a 52-week high of Rs 216.80 on 10 January 2013. The stock had hit a 52-week low of Rs 138 on 7 August 2013.
The stock had underperformed the market over the past one month till 24 October 2013, rising 2.4% compared with Sensex's 4.04% gain. The scrip had also underperformed the market over the past one quarter, advancing 2.52% as against Sensex's 3.16% rise.
Also Read
The small-cap pharmaceutical company has equity capital of Rs 18.12 crore. Face value per share is Rs 2.
It may be recalled that Unichem Laboratories' board of directors at its meeting held on 15 February 2013 had approved the sale of Indore SEZ Plant to Mylan Laboratories and members of the company had approved the sale on 29 March 2013 through postal ballot.
Unichem Laboratories' net profit rose 3.3% to Rs 36.21 crore on 1.9% growth in net sales to Rs 266.19 crore in Q2 September 2013 over Q2 September 2012.
Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world.
Powered by Capital Market - Live News